To the full analysis
Biocon stock: growth
BIOCON.NSBiocon reported $1.8B in revenue for fiscal 2026, up 10.9% on the prior year, up 18.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
17.3%
per year from 2007 to 2026, per share 16.2%
Earnings (Annual rate)
3.5%
per year from 2007 to 2026, per share 2.4%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 18.8% | 17.6% | 17.3% |
| Revenue per share | 15.5% | 15.9% | 16.2% |
| Earnings | −12.2% | −8.1% | 3.5% |
| Earnings per share | −14.7% | −4.9% | 2.4% |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $87.45M | $21.29M | −$4.12M |
| 2008 | $88.58M | $49.31M | $9.06M |
| 2009 | $145.81M | $9.9M | −$21.3M |
| 2010 | $216.44M | $31.17M | $27.02M |
| 2011 | $244.52M | $39.06M | $60.48M |
| 2012 | $217.79M | $35.97M | $28.26M |
| 2013 | $264.16M | $54.09M | $11.69M |
| 2014 | $328.41M | $43.98M | −$25.28M |
| 2015 | $328.41M | $52.87M | −$75.06M |
| 2016 | $355.79M | $95.25M | −$47.91M |
| 2017 | $413.58M | $65.06M | −$12.98M |
| 2018 | $438.27M | $39.58M | −$27.04M |
| 2019 | $586.12M | $96.22M | −$35.86M |
| 2020 | $669.67M | $79.53M | −$58.82M |
| 2021 | $759.23M | $78.71M | −$62.35M |
| 2022 | $869.86M | $68.92M | −$79.53M |
| 2023 | $1.19B | $49.18M | $13.41M |
| 2024 | $1.57B | $108.68M | $108.66M |
| 2025 | $1.62B | $107.7M | $182.59M |
| 2026 | $1.8B | $40.98M | −$55.41M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.